A Comparative, Multicenter, Open-Label, Randomized, Phase 2 Study of the Safety and Antitumor Activity of Oral Eniluracil + 5 Fluorouracil + Leucovorin Versus Capecitabine Monotherapy in Subjects With Metastatic Breast Cancer.

Trial Profile

A Comparative, Multicenter, Open-Label, Randomized, Phase 2 Study of the Safety and Antitumor Activity of Oral Eniluracil + 5 Fluorouracil + Leucovorin Versus Capecitabine Monotherapy in Subjects With Metastatic Breast Cancer.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Eniluracil (Primary) ; Capecitabine; Fluorouracil; Folinic acid
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jan 2013 Final efficacy and tolerability results are expected during the second or third quarter of 2013 according to an Adherex media release.
    • 06 Jan 2013 Status changed from recruiting to active, no longer recruiting according to an Adherex media release.
    • 09 Dec 2012 Updated interim results were presented at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium, and were reported in an Adherex media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top